Amgen Inc vs. Tarsus Pharmaceuticals, Inc. Common Stock
Amgen Inc (AMGN) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| AMGN | TARS | |
|---|---|---|
| Market Cap | $224.15 billion | $3.61 billion |
| Revenue (TTM) | $38.09 billion | $606.33 million |
| Net Income (TTM) | $8.74 billion | $-46,476,000 |
AMGN leads on 3 of 3 size & scale factors.
Valuation
| AMGN | TARS | |
|---|---|---|
| P/E Ratio | 25.75 | — |
| Price / Book | 19.18 | 10.40 |
| Price / Sales | 5.88 | 5.95 |
AMGN and TARS split the valuation factors evenly.
Profitability
| AMGN | TARS | |
|---|---|---|
| Net Margin | 22.95% | -7.67% |
| Return on Equity | 74.80% | -13.40% |
AMGN leads on 2 of 2 profitability factors.
Dividend
| AMGN | TARS | |
|---|---|---|
| Dividend Yield | 2.43% | — |
| Payout Ratio | 62.61 | — |
AMGN and TARS split the dividend factors evenly.
Risk & Sentiment
| AMGN | TARS | |
|---|---|---|
| Short Interest | 1.66% | 0.31% |
TARS leads on 1 of 1 risk & sentiment factors.
Dig deeper: AMGN overview, AMGN financials, TARS overview, TARS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.